Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

The emergence of immunotherapy revolutionized the treatment of non-small-cell-lung cancer (NSCLC), with multiple landmark clinical trials establishing the efficacy of these agents. However, many patients who receive immunotherapy in clinical practice would be considered clinical trial ineligible. On...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosjean, Heidi A. I., Dolter, Samantha, Meyers, Daniel E., Ding, Philip Q., Stukalin, Igor, Goutam, Siddhartha, Kong, Shiying, Chu, Quincy, Heng, Daniel Y. C., Bebb, D. Gwyn, Morris, Don G., Cheung, Winson Y., Pabani, Aliyah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534423/
https://www.ncbi.nlm.nih.gov/pubmed/34677275
http://dx.doi.org/10.3390/curroncol28050357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534423/
https://www.ncbi.nlm.nih.gov/pubmed/34677275
http://dx.doi.org/10.3390/curroncol28050357

Ejemplares similares